Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Avelumab ( Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 May 2021). Please note: This translation is provided as a service by IQWiG to English-language readers . However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-23 Avelumab (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-23 Version 1.0 Avelumab (urothelial carcinoma) 28 May 2021 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details
Avelumab (urothelial carcinoma) - Addendum to Commission A21-23 1 Translation of addendum A21-92 Avelumab (Urothelkarzinom) – Addendum zum Auftrag A21-23 (Version 1.0; Status: 29 July 2021). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 July 2021 1.0 Commission: A21-92 Version: Status: IQWiG Reports – Commission No. A21-92 Avelumab (urothelial carcinoma) – Addendum to Commission A21-231 Addendum A21-92 Version 1.0 Avelumab – Addendum to Commission A21-23 29 July 2021 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details
Avelumab (Bavencio) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Avelumab for merkel cell carcinoma Skip to navigationSkip to contentA-Z MedicinesFAQSubscribeSearchSearchSearch medicinePBS MEDICINE SEARCHHomePBS InformationBrowse the PBSFor Health ProfessionalsFor IndustryNewsPublications & DownloadsContactsHome/ Industry/ Listing/ Participants/ Public Release Docs/ 2022 02/ Avelumab For Merkel Cell Carcinoma 24 Month Predicted Vs Actual Analysis Feb 2022Avelumab for Merkel cell carcinoma: 24 month predicted versus actual analysis, February 2022Page last updated: 4 July 2022Drug utilisation sub-committee (DUSC)February 2022AbstractPurposeAnalysis of the predicted versus actual utilisation of avelumab 24 months following its addition to the Pharmaceutical Benefits Scheme (PBS) for the treatment of metastatic Merkel cell carcinoma (MCC) on 1 May 2019.Data
Avelumab (Bavencio) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Summary of Cohere Finland's recommendation concerning the use of avelumab as first-line treatment for urothelial carcinoma SUMMARY 1 September 2021 1(3) STM051:00/2020 VN/11021 /2021 Meritullinkatu 8, Helsinki PO BOX 33, 00023 GOVERNMENT, FINLAND Tel. +358 295 16001 www.palveluvalikoima.fi e-mail: palveluvalikoima@stm.fi SUMMARY OF A RECOMMENDATION BY COHERE FINLAND ON AVELUMAB AS FIRST -LINE TREATMENT FOR UROTHELIAL CARCINOMA The Council for Choices in Health Care in Finland (COHERE Finland) approved the rec-ommendation at its meeting on 1 September 2021. According to the recommendation, avelumab is included in the range of choices in the first-line treatment of locally advanced or metastatic urothelial carcinoma in patients who are progression-free following platinum-based
Package advice on avelumab (Bavencio) for treating urothelial cell carcinoma Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma | Report | National Health Care Institute Go to content You are here: Home Publications Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma Search within English part of National Health Care Institute Search Package advice on avelumab (Bavencio®) for treating urothelial cell carcinomaZorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. Avelumab is indicated as monotherapy for the primary-care maintenance treatment of adult patients with locally advanced or metastatic urothelial cell carcinoma. The reason for this advice was the placing
Avelumab (Bavencio) - for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma 1 Published 09 August 2021 1 SMC2359 avelumab 20mg/mL concentrate for solution for infusion (Bavencio®) Merck KGaA, Pfizer Ltd 09 July 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan equivalent process avelumab (Bavencio®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic
Avelumab (Bavencio) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021 Grössmann, N.(2020):Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment
Avelumab (Bavencio) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma | Report | National Health Care Institute Go to content You are here: Home Publications Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma Search within English part of National Health Care Institute Search Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinomaThe National Health Care Institute has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed following platinum-based chemotherapy in France. A three-state partitioned survival model was developed to assess the lifetime costs and effects of avelumab plus BSC versus BSC alone. Data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) were used to inform estimates of clinical and utility values considering a 10-year time horizon and a weekly cycle length. Cost data were estimated from
Avelumab (Bavencio) - Urothelial carcinoma Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical
Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer. Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative avelumab to standard treatments. Patients with resectable E/GEJ cancers received avelumab with nCRT and adjuvant avelumab after resection. Primary endpoints for phase I and II portions were safety and pathologic complete response (pCR) rate, respectively. Secondary endpoints included recurrence-free survival (RFS), surgical complication prevalence, and R0 resection rate. Twenty-two patients enrolled
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Checkpoint agonists utomilumab (4-1BB agonist) and ivuxolimab (OX40 agonist) enhance Teffector cell function. Preclinical studies suggest that combining these drugs with avelumab (anti-PD-L1 antibody) can potentially synergize this effect . In addition, tissue abscopal effects of radiation therapy may improve antigen presentation, complementing PD-L1 blockade. We conducted a single institution, open-label, multi-arm, non-randomized, phase 1/2 clinical trial of avelumab in combination with ivuxolimab, with or without utomilumab, and radiation therapy in patients with advanced solid tumors. Herein, we present a subgroup analysis in patients
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial Although most patients with epithelial ovarian cancer respond to frontline platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 JAVELIN Ovarian 100 trial compared avelumab (anti-PD-L1 monoclonal antibody) in combination with chemotherapy followed by avelumab maintenance, or chemotherapy followed by avelumab maintenance, versus chemotherapy alone in patients with treatment-naive epithelial ovarian cancer. JAVELIN Ovarian 100 was a global, open-label, three-arm, parallel, randomised, phase 3 trial run at 159 hospitals and cancer treatment
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-line treatment with avelumab given concurrent to chemotherapy and as maintenance after the end of chemotherapy. MITO END-3 is an open-label, randomised, controlled, phase 2 trial conducted at 31 cancer institutes, hospitals, and universities in Italy. Eligible patients were aged 18 years or older with histologically confirmed advanced (FIGO stage III-IV
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free following 1L platinum-based chemotherapy, leading to regulatory approval in various countries. To analyze clinically relevant subgroups from JAVELIN Bladder 100. Patients with unresectable locally advanced or metastatic UC without progression on 1L gemcitabine + cisplatin or carboplatin were randomized to receive avelumab + BSC (n = 350) or BSC alone (n